Moreover, other novel treatments can be considered in future research and trials such as pegcetacoplan, a C3 inhibitor of the alternative complement pathway, that was used and showed a promising result in autoimmune hemolytic anemia (24). This evidence concerns the gene C3 and autoimmune hemolytic anemia.